Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Nov 28, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.6K

Interim PET in Diffuse Large B-Cell Lymphoma.

Lars Kurch1, Andreas Hüttmann2, Thomas W Georgi3

  • 1Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Leipzig, Leipzig, Germany; lars.kurch@medizin.uni.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|November 28, 2020
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

E Lesion or Stage IV disease? An Ongoing Unsettled Issue in Pediatric Hodgkin Lymphoma.

Blood advances·2026
Same author

​EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

Blood advances·2026
Same author

Circulating miR-148a-3p Correlates with Inadequate Induction Response in Pediatric Hodgkin Lymphoma.

ImmunoTargets and therapy·2026
Same author

A convolutional neural network for fully automated total metabolic tumor volume delineation in patients with aggressive Non-Hodgkin lymphoma.

European journal of nuclear medicine and molecular imaging·2026
Same author

Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer.

European urology oncology·2026
Same journal

Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRI.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Erratum.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Live from 2026 SNMMI Annual Meeting in Los Angeles!

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
See all related articles
This summary is machine-generated.

Continuous scales like qPET and ΔSUVmax are superior for predicting diffuse large B-cell lymphoma treatment response on interim PET scans compared to the Deauville score. These quantitative methods offer more reliable early identification of therapy effectiveness.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Medical imaging

Background:

  • Early assessment of treatment response in diffuse large B-cell lymphoma (DLBCL) using 18F-FDG PET is crucial for treatment modification.
  • Reliable identification of good and poor responders is essential for optimizing patient outcomes.
  • Current methods for interim PET evaluation in DLBCL need robust comparison.

Purpose of the Study:

  • To compare the efficacy of three competing methods for interim 18F-FDG PET evaluation in DLBCL patients.
  • To assess the predictive value of visual Deauville score, quantitative PET (qPET), and ΔSUVmax for progression-free survival.
  • To determine if continuous scales offer improved outcome prediction over ordinal scales.

Main Methods:

  • Reanalysis of interim PET scans from 449 DLBCL patients in the "PET-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" trial.
Keywords:
Deauville scalePETPETAL trialdiffuse large B-cell lymphomainterim evaluationqPETΔSUVmax

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.2K

Related Experiment Videos

Last Updated: Nov 28, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.6K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.2K
  • Application of visual Deauville score, qPET (quantitative uptake relative to liver uptake), and ΔSUVmax (change in maximum standardized uptake value) after 2 chemotherapy cycles.
  • Calculation of positive and negative predictive values for progression-free survival.

    • Main Results:

    • Continuous scales (qPET and ΔSUVmax) demonstrated significantly higher positive predictive values for identifying poor responders compared to the visual Deauville score (56.6% vs. 38.4%).
    • qPET and ΔSUVmax showed strong correlation (Pearson r = 0.75) and superimposable positive predictive value curves, indicating they carry similar prognostic information.
    • The established threshold for poor responders (ΔSUVmax > 66% reduction) corresponded to qPET = 2.26, equivalent to Deauville score 5.

    Conclusions:

    • Continuous quantitative scales (qPET and ΔSUVmax) are better suited for interim PET-based outcome prediction in DLBCL than the ordinal Deauville scale.
    • qPET and ΔSUVmax provide essentially equivalent prognostic information for treatment response.
    • Quantitative methods identify a smaller proportion (less than 15%) of poor-risk patients, allowing for more precise treatment stratification.